Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapyBeth L. Thurberg, M. W. O'CALLAGHAN, Helmut G. Rennke et al.|Kidney International|2002Cited by 331
Enzyme replacement therapy in the mouse model of Pompe diseaseNina Raben, Paul H. Plötz, M. J. Danon et al.|Molecular Genetics and Metabolism|2003Cited by 215
Replacing acid α-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibersNina Raben, Paul H. Plötz, Tokiko Fukuda et al.|Molecular Therapy|2004Cited by 138
A randomized, placebo-controlled clinical trial evaluating olipudase alfa enzyme replacement therapy for chronic acid sphingomyelinase deficiency (ASMD) in adults: One-year resultsMelissa Wasserstein, Monica Kumar, Paulina Mabe et al.|Genetics in Medicine|2022Cited by 99
Biochemical and pharmacological characterization of different recombinant acid α-glucosidase preparations evaluated for the treatment of Pompe diseaseAlison McVie‐Wylie, Robert J. Mattaliano, K.L. Lee et al.|Molecular Genetics and Metabolism|2008Cited by 96